secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0000950170-24-026877
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel accelerates unveiling of second enLIGHTEN candidate to AACR April 2024
-----------------------------------------------------------------------------

- Second enLIGHTEN platform candidate to be presented at AACR April 9, 2024; originally planned for Q3 2024.
- First-in-class multimodal immunotherapy designed to induce tertiary lymphoid structures for solid tumors.
- Abstract LB263; poster session on Tuesday April 9, 9:00 AM - 12:30 PM PT in San Diego.
- Candidate follows Alpha 201-macro-1; data from preclinical models shown at SITC 2023 and Oncolytic Virus Conference 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024026877/0000950170-24-026877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024026877/cadl-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-026877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer